Background/Objectives: Brimonidine tartrate (BRT), a selective α2-adrenergic receptor agonist, is commonly used in the treatment of glaucoma. However, conventional eye drop formulations suffer from poor ocular bioavailability and rapid elimination. This study aimed to develop and evaluate BRT-loaded ethosomes as a nanocarrier-based alternative to enhance intraocular delivery and therapeutic efficacy. Methods: Ethosomes were prepared using the thin-film hydration method and optimized via central composite design. The optimized formulation was subjected to physicochemical characterization, in vitro release testing, and ocular irritation assessment using the Hen egg test—chorioallantoic membrane (HET-CAM) model. Additionally, the intraocular pressure (IOP)-lowering efficacy of the formulation was evaluated in a rat glaucoma model. Results: The optimized ethosomal formulation exhibited favorable physicochemical properties, including a mean particle size of 122.6 ± 0.7 nm, zeta potential of −1.8 ± 0.9 mV, and encapsulation efficiency of 87.33 ± 0.04%. In vitro release data followed Higuchi kinetics. HET-CAM analysis indicated non-irritancy. In vivo, the ethosomal BRT formulation achieved comparable IOP-lowering effects to the marketed eye drops at one-third of the dose. Conclusions: The developed BRT-loaded ethosomal system demonstrated promising physicochemical stability, sustained release, and therapeutic potential. These findings suggest that ethosomes may offer a safe and effective strategy for enhancing the ocular delivery of BRT in glaucoma therapy.
Aims: Probiotics are widely used to restore microbiota balance and prevent dysbiosis. In this study, the aim was to develop mucoadhesive vaginal tablets containing probiotic Lactobacillus gasseri H14 and H15 strains, representing low and high exopolysaccharide (EPS) producers, respectively, and isolated from the vaginal microbiota of healthy women. Methods and results: Mucoadhesive polymers were employed to prolong the residence of lactobacilli on the vaginal epithelium, thereby facilitating colonization. To preserve bacterial viability and minimize the adverse effects of the tableting process, lyophilization was applied before direct compression. Tablets were prepared using different mucoadhesive polymers, including polyacrylic acid, sodium alginate, and hydroxypropyl methylcellulose (HPMC). The influence of EPS production levels of L. gasseri H14 and H15 strains, and polymer type on bacterial adhesion was assessed using HeLa cell assays, while bacterial viability was determined by colony counts. In vitro release of bacteria from compressed tablets was evaluated under static conditions. Among the strains, L. gasseri H15 was identified as the most suitable candidate due to its high post-lyophilization viability and strong adhesion to epithelial cells. Considering swelling, disintegration, and mucoadhesive properties, HPMC was selected as the optimal excipient. Overall, the findings demonstrated that lyophilization and tableting with mucoadhesive polymers did not impair the adhesion capacity of L. gasseri H15 to epithelial cells. Conclusions: A stable vaginal solid dosage form containing viable probiotic bacteria was successfully developed, preserving their functional adhesion properties.